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Discussion
Dr Todd K. Rosengart (Houston, Tex). Congratulations,
Dr Bridges, again, on very nice work and thank you for allowing
me to review your report in advance.
As you rightly note, and I would reiterate, there is a lack of
appreciation that many experimental and clinical cardiac gene
therapy trials have been encumbered by inadequate substrate
delivery, just as we have heard in the earlier presentations, and
again we applaud you for your diligent effort in pursuing this.1072 The Journal of Thoracic and Cardiovascular SurThe MCARD technique, I think, remains limited in the sense
that you do need cardiopulmonary bypass. Also, I am sure you
have looked very diligently at this, but the question is: Is there
any way to accomplish the MCARD technique without actually
instituting cardiopulmonary bypass, such as through a blood
recirculation technique?
In regard to your data in the current technique, my second
question, which was in your report, is even though you have
effectively shown much higher levels of cardiac uptake compared
to the liver, you did still have NAbs in your controls. Do you have
any further plans to improve isolation or address this issue?
Finally, recognizing that time did not allow your addressing this
issue, we know the retrograde perfusion technique preferentially de-
livers to the left ventricle andbypasses the right ventricle and septum.
Your expression with MCARD, I believe, has been heterogeneous
because of this. Are there any approaches that you could add to
your technique to improve right ventricular and septal delivery?
Again, congratulations on this very nice work.
Dr Bridges.Well, thanks, Todd, it is certainly a pleasure and an
honor to have our report reviewed by one of the pioneers in cardiac
gene therapy. Dr Rosengart conducted the first clinical trial of gene
therapy using cardiac surgery as a delivery platform more than a
decade ago. So, thank you for the opportunity to discuss this
with you.
Your first question was: Molecular cardiac surgery with
recirculating delivery, can it be done without cardiopulmonary
bypass? And that has been tried. I published a letter to the editor
in Gene Therapy in 2009 in which a ‘‘recirculating’’ delivery
technique known as ‘‘V-Focus’’ was reported that purported to
isolate the heart in situ. In fact, they actually did use a perfusion
circuit, so even that was not without cardiopulmonary bypass.
However, owing to the complexities of the cardiac circulation
with the Thebesian veins, for example, and in the sheep model
with the hemizygous vein, it is really difficult, if not impossible,
to effectively isolate the heart without cardiopulmonary bypass,
at least at present. Of course, that remains an open question. We
have developed some technology that should allow us to do it
minimally invasively, but at present, to achieve the 99%
efficacious separation of the 2 circuits requires cardiopulmonary
bypass. However, we are certainly interested in pursuing other
options, which might not be perfect but would enhance the
effectiveness of catheter-based delivery.
Your second question was the NAbs. We did, in fact, see
evidence of NAbs in our experimental group despite our 99%
efficient separation of the cardiac from the systemic circulation.
We published a report in the Journal of Cardiac Failure in 2011,
which was a pharmacokinetic analysis. The concern is patients
who have NAbs before you administer the gene therapy, which
decreases the efficacy of the gene delivery. If a patient develops
NAbs after gene delivery, it might or might not have an effect on
subsequent treatment but will not affect the efficacy of the therapy.
However, with most of these gene therapy protocols, one-time
treatment is really what we expect is likely to be efficacious, so
hopefully that will not be an important limitation. Apparently,
even the small amounts of antibody of the viral vector that moved
into the circulation with our technique, which, again, was orders of
magnitude less than with the intracoronary approach, was enough
to provoke a NAb.gery c September 2014
Katz et al Evolving Technology/Basic ScienceFinally, your question was about retrograde versus antegrade.
As you know, retrograde delivery more effectively transduces or
provides nutrient flow using retrograde cardioplegia to the left
ventricle and is less efficient in the right ventricle; and, in fact,
that is what we have seen in our work, in our previously published
work, as recently as a report published in August 2013 in the
Annals of Thoracic Surgery. However, although we have seen bet-The Journal of Thoracic and Carter transduction of the left ventricle than the right ventricle, we
have seen at least 10 to 100 times better transduction of even the
right ventricle using this technique than with the intracoronary de-
livery method. Thus, hopefully, that will still be enough to achieve
efficacy on the right side. Also, you could combine retrograde with
antegrade. Thus, a number of potential strategies exist that might
allow us to overcome that.diovascular Surgery c Volume 148, Number 3 1073
E
T
/B
S
